Shopping Cart

There are no products in your cart.

Janson Tse

PhD Student

More about Janson Tse

As a translational cancer researcher I have the opportunity to provide frontline research which can directly influence cancer patient survival outcomes. Knowing that my work may one day help patients and assist in the battle against cancer is why I strive to be a cancer researcher.

My interest in research began in my undergraduate degree where I majored in Pharmaceutical Sciences in 2010 at RMIT University. The link between drug discovery to patient bedside was always my area of interest. Having undertaken a one year internship at CSL Biotherapies in the final year of my undergraduate degree, I realised that many new drugs had the propensity to fail when moving from initial discovery into clinical trials. Hence, I set my goal to aid in the improvement in understanding and properly identifying how investigative drugs worked in order to improve and strengthen their chances in clinical trials.

After my undergraduate degree I undertook an honours degree in 2011, in the Oncogenic Transcription Laboratory at the Ludwig Institute for Cancer Research, Melbourne, Australia, in partnership with the University of Melbourne. My work was to investigate the combinatorial use of Histone De-acetylase inhibitors (HDACi) and proteasome inhibitors for the treatment of colorectal cancer.

In 2012 I received an Australian Post-graduate Award to pursue my PhD in the same laboratory further pursuing the HDACi and proteasome inhibitor combination, and also further investigating the mechanisms of HDACi induced apoptosis to further identify rational drug combinations to treat a wide variety of solid tumour cancers. I am currently in the middle of completing my thesis and publications.